Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor - PubMed (original) (raw)
. 1995 Jun 16;270(24):14477-84.
doi: 10.1074/jbc.270.24.14477.
Affiliations
- PMID: 7782309
- DOI: 10.1074/jbc.270.24.14477
Free article
Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor
L Bajzar et al. J Biol Chem. 1995.
Free article
Abstract
Previous studies demonstrated that tissue plasminogen activator-induced fibrinolysis in vitro is retarded in the presence of prothrombin (II) activation and that the anticoagulant-activated protein C appears profibrinolytic by preventing the formation of thrombin (IIa)-like activity during fibrinolysis. To disclose the molecular connection between the generation of IIa and the inhibition of fibrinolysis, a lysis assay that is sensitive to the antifibrinolytic effect of II activation was developed and was used to purify a 60-kDa single-chain protein from human plasma. Because the lysis of a clot, produced from purified components, is retarded when this protein is present and when II activation occurs in situ, the protein was named TAFI (thrombin-activatable fibrinolysis inhibitor). TAFI is cleaved by IIa yielding 35-, 25-, and 14-kDa products. Amino-terminal sequence analyses identified TAFI as a precursor of a plasma carboxypeptidase B (CPB). Formation of the 35-kDa product correlates with both prolongation of lysis time and CPB-like activity. Prolongation of lysis time saturates at about 125 nM TAFI. Activated TAFI inhibits the activation of Glu-plasminogen but does not prolong the lysis of clots formed in the presence of Lys-plasminogen. 2-Guanidinoethylmercaptosuccinic acid, a competitive inhibitor of CPB, completely inhibits prolongation of lysis by activated TAFI in a purified system and the prolongation induced by II activation in barium-adsorbed plasma. This suggests that TAFI accounts for the antifibrinolytic effect that accompanies prothrombin activation and that activated protein C appears profibrinolytic by attenuating TAFI activation.
Similar articles
- Both cellular and soluble forms of thrombomodulin inhibit fibrinolysis by potentiating the activation of thrombin-activable fibrinolysis inhibitor.
Bajzar L, Nesheim M, Morser J, Tracy PB. Bajzar L, et al. J Biol Chem. 1998 Jan 30;273(5):2792-8. doi: 10.1074/jbc.273.5.2792. J Biol Chem. 1998. PMID: 9446587 - The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent.
Bajzar L, Nesheim ME, Tracy PB. Bajzar L, et al. Blood. 1996 Sep 15;88(6):2093-100. Blood. 1996. PMID: 8822928 - Thrombin-mediated activation of factor XI results in a thrombin-activatable fibrinolysis inhibitor-dependent inhibition of fibrinolysis.
Von dem Borne PA, Bajzar L, Meijers JC, Nesheim ME, Bouma BN. Von dem Borne PA, et al. J Clin Invest. 1997 May 15;99(10):2323-7. doi: 10.1172/JCI119412. J Clin Invest. 1997. PMID: 9153272 Free PMC article. - Thrombin activatable fibrinolysis inhibitor and an antifibrinolytic pathway.
Bajzar L. Bajzar L. Arterioscler Thromb Vasc Biol. 2000 Dec;20(12):2511-8. doi: 10.1161/01.atv.20.12.2511. Arterioscler Thromb Vasc Biol. 2000. PMID: 11116046 Review. - [Regulatory mechanism of fibrinolysis system by thrombin activatable fibrinolysis inhibitor (TAFI)].
Urano T. Urano T. Nihon Yakurigaku Zasshi. 2000 Nov;116(5):298-303. doi: 10.1254/fpj.116.298. Nihon Yakurigaku Zasshi. 2000. PMID: 11215380 Review. Japanese.
Cited by
- Activated thrombin-activatable fibrinolysis inhibitor is generated in vivo at levels that can substantially affect fibrinolysis in chimpanzees in response to thrombin generation.
Kim PY, Kim PY, Hoogendorn H, Giles AR, Nesheim ME. Kim PY, et al. J Thromb Haemost. 2008 Sep;6(9):1600-2. doi: 10.1111/j.1538-7836.2008.03067.x. Epub 2008 Jul 4. J Thromb Haemost. 2008. PMID: 18624981 Free PMC article. No abstract available. - A genome-wide exploration suggests an oligogenic model of inheritance for the TAFI activity and its antigen levels.
Sabater-Lleal M, Buil A, Souto JC, Alamsy L, Borrell M, Lathrop M, Blangero J, Fontcuberta J, Soria JM. Sabater-Lleal M, et al. Hum Genet. 2008 Aug;124(1):81-8. doi: 10.1007/s00439-008-0527-3. Epub 2008 Jun 18. Hum Genet. 2008. PMID: 18563448 Free PMC article. - Carboxypeptidase U (CPU, TAFIa, CPB2) in Thromboembolic Disease: What Do We Know Three Decades after Its Discovery?
Claesen K, Mertens JC, Leenaerts D, Hendriks D. Claesen K, et al. Int J Mol Sci. 2021 Jan 17;22(2):883. doi: 10.3390/ijms22020883. Int J Mol Sci. 2021. PMID: 33477318 Free PMC article. Review. - Characteristics of fibrin formation and clot stability in individuals with congenital type IIb protein C deficiency.
Foley JH, Ferris L, Brummel-Ziedins KE. Foley JH, et al. Thromb Res. 2012 Apr;129(4):e142-6. doi: 10.1016/j.thromres.2011.12.020. Epub 2012 Jan 13. Thromb Res. 2012. PMID: 22245244 Free PMC article. - Increased thrombin-activatable fibrinolysis inhibitor levels in patients with chronic rhinosinusitis with nasal polyps.
Imoto Y, Kato A, Takabayashi T, Stevens W, Norton JE, Suh LA, Carter RG, Weibman AR, Hulse KE, Harris KE, Peters AT, Grammer LC, Tan BK, Welch K, Shintani-Smith S, Conley DB, Kern RC, Fujieda S, Schleimer RP. Imoto Y, et al. J Allergy Clin Immunol. 2019 Dec;144(6):1566-1574.e6. doi: 10.1016/j.jaci.2019.08.040. Epub 2019 Sep 25. J Allergy Clin Immunol. 2019. PMID: 31562871 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials